Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple-ascending-dose intrathecal BIIB078 study in adults with C9ORF72-associated amyotrophic lateral sclerosis
NL-OMON46750Phase 1Withdrawn
- Sponsor
- Biogen
- Start
- May 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of tadnersen in amyotrophic lateral sclerosis (ALS), sponsored by Biogen. Planned start May 2018; status: withdrawn.
02
Drugs
tadnersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON46750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46750.